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S1. General experimental section and synthetic procedures
General experimental procedures
Reagents were purchased from commercial sources and used as received. CdSe/ZnS quantum dots, 5-amino-
2,2’-bipyridine and 5-bromo-2,2’-bipyridine were synthesized according to literature procedures.[1] 1H-NMR, 
13C-NMR, HMQC and HMBC were performed on a Bruker Avance III spectrometer operating at 500 MHz. 
High resolution mass spectra were measured with a Bruker FTMS 4.7T BioAPEXII spectrometer. IR spectra 
were measured with a Bruker Tensor 27. UV-Vis spectroscopy was performed using a Perkin-Elmer Lambda 
35. Irradiation at 510 nm was performed using an Edinburgh FS5 fluorimeter (excitation slit: 1 nm) equipped 
with a 150 W Xe lamp. Time-resolved fluorescence decay were obtained using an Edinburgh LifeSpec II 
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fluorimeter equipped with a LED excitation source (406 nm, repetition rate 100 ns) and collecting the 
emission light at 520 nm. An excitation vertical polarization and an emission polarization filter oriented at 
the magic angle 54.7° was used to remove depolarisation effects. The fitting of the lifetime decay was 
performed with the software provided by Edinburgh. Photodecomposition kinetics were calculated upon 
fitting of the monoexponential decay by using the software Origin 7.5.  
 
4-[2,2’-bipyridin]-4-ylethynyl)benzoic acid (Ligand L2). 60 mg (0.26 mmol) of 4-bromo-2,2’-bipyridine 
are dissolved in 20 ml of dry acetonitrile and 6 mg (0.023 mmol) of Pd(CH3CN)2Cl2, 27 mg (0.057 mmol) of 
XPhos (XPhos = 2-cyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl) and 200 mg (0.6 mmol) of Cs2CO3 
are added. The resulting suspension is degassed with 3 Ar/vacuum cycles and stirred 1 h under Ar 
atmosphere. 45 mg (0.28 mmol) of methyl 4-ethynylbenzoate are added and the resulting mixture is heated at 
80°C for 24 h under Ar atmosphere. The solvent is then evaporated and the crude is dissolved in 50 ml of 
chloroform and washed 3 times with 30 ml of water, then with 30 ml of brine and the organic phase is 
eventually dried over Na2SO4. The solvent is then removed and the resulting solid is purified by 
crystallization from boiling methanol. The resulting product is dissolved in 30 ml of THF and treated 
overnight with 10 ml of an aqueous solution of NaOH 1M at room temperature. After THF evaporation, the 
free acid is precipitated upon acidification of the aqueous solution with HCl. Obtained 20 mg of pure product 
(0.07 mmol; 30% overall).    
1H-NMR (500 MHz, d6-DMSO): L  (ppm)= 13.26 (br s, 1H), 8.78 (d, 2H, J = 5 Hz), 8.73 (d, 2H, J = 4 Hz), 
8.52 (s, 1H), 8.44 (d, 1H, J = 7 Hz), 8.06-7.99 (m, 3H), 7.77 (d, 2H, J = 6 Hz), 7.66 (d, 1H, J = 6 Hz), 7.54 (t, 
1H, J = 6 Hz). 13C-NMR (125 Hz, d6-DMSO) L = 156.5, 155.9, 153.6, 149.6, 148.9, 138.2, 132.0, 131.4, 
131.0, 129.6, 125.7, 126.4, 124.9, 92.9, 89.9. HR-ESI (m/z): Calc. for C19H13N2O2 [M + H]+: 301.0977. 
Found: 301.0973.  
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Figure S1. 1H NMR (top) and 13C NMR (bottom) of ligand L2 in d6-DMSO.  
4-[2,2’-bipyridin]-4-ylethynyl)aniline (Ligand L4).  540 mg of 4-bromo-2,2’-bipyridine (2.3 mmol), (236 
mg, (0.5 mmol) of XPhos, 1.7 mg of Cs2CO3 (5 mmol) and 49 mg of Pd(CH3CN)2Cl2 (0.19 mmol) are 
dissolved in 50 ml of CH3CN. The mixture is degassed with three Ar/vacuum cycles and stirred at room 
temperature for 1 hour before adding 292 mg of 4-ethynylaniline (2.5 mmol). The mixture is refluxed for 2 
days under N2. The solvent is removed and the brownish oil is purified by column chromatography on a SiO2 
column using CH2Cl2/MeOH, 98:2 as eluting solvent to yield ligand L4 (370 mg, 1.38 mmol; 60%). 100 mg. 
1H-NMR (500 MHz, CDCl3): L  (ppm): 8.71 (d, 1H, J = 5 Hz), 8.63 (d, 1H, J = 5 Hz), 8.48 ( s, 1H), 8.41 (d, 
1H, J = 8 Hz), 7.64 (t, 1H, J = 8 Hz), 7.38-7.33 (m, 4H), 6.66 (d, 2H, J = 8 Hz). 13C-NMR (125 Hz, CDCl3): 
L (ppm) = 156.0, 155.7, 149.2, 149.0, 147.5, 137.0, 133.5, 133.2, 125.0, 124.0, 123.0, 121.1, 114.7, 111.4, 
95.4, 85.4. HR-ESI (m/z) : Calc. for C18H14N3  [M + H]+: 272.1188. Found: 272.1180.  
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Figure S2. 1H NMR (top) and 13C NMR (bottom) of ligand L4 in CDCl3.
Synthesis of fac-[Mn(CO)3LBr] complexes.
Species 1-4 were synthesized according to the procedure described by Sampson et al. with slight 
modifications.[2] Briefly. Mn(CO)5Br (100 mg, 0.37 mmol) was added to 15 mL of diethyl ether (Et2O) in 
ambient air. The selected ligand (0.37 mmol) was added to the mixture and heated to reflux. For species 2-4 
the solution turned orange within 60 min, and the product precipitated out of solution. After 3 h, the mixture 
was cooled to room temperature, and the precipitate was filtered off and washed with Et2O. The orange solid 
was then dried overnight under vacuum. For species 1 the precipitate was identified as a mixture of 
unreacted ligand and Mn(CO)5Br. The reaction mixture was filtered off and the solution containing 1 was 
dried under vacuum. Compounds were then purified via HPLC. All compounds show a dynamic equilibrium 
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in the presence of coordinating solvents. Such equilibrium can be shifted towards the formation of a single 
species upon addition of an excess of KCN, as evidenced by the NMR shown in Figure S8. Therefore when 
needed (complexes 1, 2, and 4) KCN was added to the NMR solutions. 
Analytical HPLC method. Instrument: MERCK HITACHI LaChrom with a D-7000 interface coupled with a 
Diode Array detector L-7455 and a pump L-7100 system. Column: Macherey-Nagel, EC250/3 Nucleosil 
100-5 C18. Flow rate 0.5 mL/min. Absorbance monitored at 250 nm. Solutions: A: 0.1% trifluoroacetic acid 
in water; B: methanol. Chromatographic method: 0-5 min: isocratic flow of 75% A - 25% B; 5-35 min: linear 
gradient to 100% B; 35-45 min: isocratic flow of 100% B.
Analytical data for 1:  Yield 65 mg (24%). HPLC retention time (min): 21.17. 1H-NMR (500 MHz, CD3OD 
+ KCN): L (ppm) = 9.11  (d, 2H, J = 6 Hz ), 8.88 (s, 2H), 8.02 (d, 2H,  , J = 6 Hz). 13C-NMR (125 MHz, 
CD3OD + KCN): see figure S3.  IR (KBr) QCO: 2027, 1943, 1913, 1733 cm-1. HR-ESI (m/z) : Calc. for 
C15H7BrMn N2O7  [M - H]-: 460.8823. Found: 460.8826.  
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Figure S3. (from top to bottom) 1H-NMR, 13C-NMR, HMQC/HMBC-NMR (aromatic region) spectra 
(CD3OD + KCN) with 1H and 13C signals assignment of 1  and  HPLC chromatogram. * = KCN 
methanolysis product, ** = KCN. 
Analytical data for 2:  Yield 150 mg (78%). HPLC retention time (min): 27.99. IR (KBr) QCO: 2026, 1925, 
1736 cm-1. HR-ESI (m/z) : Calc. for C22H11BrMn N2O5  [M - H]-: 518.9217. Found: 518.9218.  Although this 
species was isolated as a single HPLC peak, it undergoes a rapid equilibrium (see Figure S5) giving two 
HPLC peaks having identical mass (m/z : 439.0 [M-Br]+). This equilibrium mixture cannot be completely 
shifted by addition of KCN, therefore the 1H-NMR spectrum of the unresolved mixture is given, along with 
the tentative peak assignment of the major and minor species (relative ratio: 1.4:1). 
Major species: 1H-NMR (500 MHz, CD3OD + KCN): L (ppm) = 9.10 (d, 1H, J= 5Hz), 9.06 (d, 1H, J = 6 
Hz), 8.67-8.65 (m, 2H), 8.21 (t, 1H, J = 7 Hz), 8.0 (d, 2H, J = 8 Hz), 7.73 (d, 1H, J = 6 Hz), 7.70 (t, 1H, J = 7 
Hz), 7.64 (d, 2H, J = 8 Hz). 
Minor species: 1H-NMR (500 MHz, CD3OD + KCN): L (ppm) = 8.60 (d, 2H, J = 8 Hz), 8.40 (s, 1H), 8.34 (d, 
1H, J = 8Hz), 7.99-7.94 (m, 3H), 7.58 (d, 2H, J = 8Hz), 7.53 (d, 1H, J = 5 Hz), 7.47 (t, 1H, J = 7 Hz). 
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Figure S4 1H-NMR of  2  (CD3OD + KCN).  * = KCN methanolysis product. 
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Figure S5. HPLC chromatograms of 2 showing the equilibration of the purified species upon standing. 
Analytical data for 3:  Yield 90 mg (62%). HPLC retention time (min): 21.95. 1H-NMR (500 MHz, d6-
DMSO + D2O): L (ppm)  = 9.02 – 9.00  (m, 2H), 8.83 (d, 1H, J = 6 Hz ), 8.77 (d, 1H, J = 8 Hz), 8.29 (t, 1H, J 
= 8 Hz), 7.97 (dd, 1H, J = 6 Hz), 7.75 (t, 1H, J = 6 Hz.  ). 13C-NMR (125 MHz, d6-DMSO+D2O): see figure 
S6. IR (KBr) QCO: 2022, 1940 cm-1. HR-ESI (m/z) : Calc. for C13H9Mn N3O3  [M - Br]+: 310.0024. Found: 
310.0024. 
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Figure S6. (from top to bottom) 1H-NMR, 13C-NMR, HMQC/HMBC-NMR (aromatic region) spectra (d6-
DMSO + trace of D2O) with 1H and 13C signals assignment of 3  and  HPLC chromatogram.
Analytical data for 4:  Yield 108 mg (60%). HPLC retention time (min): 26.45. 1H-NMR (500 MHz, 
CD3OD+KCN): L (ppm) = 9.09 (d, 1H, J = 5 Hz), 8.97 (d, 1H, J = 6 Hz), 8.57 (d, 1H, J = 8 Hz), 8.53 (s, 1H), 
8.20 (t, 1H, J = 8 Hz), 7.69 (t, 1H, J = 7 Hz), 7.61 (d, 1H, J = 6 Hz), 7.35 (d, 2H, J = 7 Hz), 13C-NMR (125 
MHz, CD3OD + KCN): see figure S7.  IR (KBr) QCO: 2023, 1928, 1910 cm-1. HR-ESI (m/z) : Calc. for 
C21H13Mn N3O3 [M - Br]+: 410.0337. Found: 410.0331.  
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Figure S7. (from top to bottom) 1H-NMR, 13C-NMR, HMQC/HMBC-NMR (aromatic region) spectra 
(CD3OD + KCN) with 1H and 13C signals assignment of 4  and  HPLC chromatogram.. ** = KCN.
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Figure S8. Evidence of ligand exchange equilibrium upon addition of KCN to a CD3OD solution of 4.  
S2. Synthesis of QD-Mn conjugates and estimation of [Mn]:[QD] ratio.
0.5 ml of the stock solution0.038 mM of QD in THF were added to 5 equivalents of Mn complex suspended 
in 1.5 ml of THF (in the case of complexes 3 and 4, the compounds were previously treated with 0.1 ml of 
CS2 for 1h and then dried under vacuum). The resulting mixture was stirred overnight in the dark and then 
centrifuged to remove unreacted complex. The conjugated were then characterised by UV-Vis and used 
without further purification. For the irradiation test, 0.1 ml of this solution were dissolved in 1.8 ml of THF 
and 0.1 ml of MeOH. 
To evaluate the [Mn]:[QD] ratio, the UV-Vis of the conjugated was compared with an equimolar solution of 
QD prepared by following the same procedure but without addition of Mn complexes (Figure S9). The 
estimation of the [Mn]:[QD] ratio in conjugate QD-1 is here given as example. 
By assuming the additivity of absorption spectra, the Mn contribution to the absorption at 313 nm 
313Abs(Mn)QD-1   was evaluated using the equation
313Abs(Mn)QD-1 =313AbsQD-1 – 313AbsQD
where 313AbsQD-1 and  313AbsQD are the absorption of the QD-1 conjugate solution and of the QD solution at 
313 nm, respectively. 
[Mn] concentration is then evaluated using Lambert-Beer equation and the previously determined  of 1.  
[QD] is evaluated using the literature procedure.[3] 
In the case of QD-1, the obtained values are
313Abs(Mn)QD-1 =0.13 
[Mn]QD-1 = 0.13 / 15063 = 8.6.10-5 M.
[QD] = 5.10-6 M 
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Figure S9. UV-Vis absorption spectrum of equimolar solutions of QD and of QD-Mn used for the estimation 
of [Mn]:[QD] ratio.  
S3. UV-Vis spectra of Mn(I) complexes and integral overlapping with CdSe/ZnS QD emission.
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The overlapping integral (J) was calculated using the software a/e UV-Vis-IR Spectral Software (v. 2.0) 
available on www.fluorotools.com. 
S4. Calculation of the normalised quenching constants
Quenching constants normalised according to the number of Mn(I) complexes attached to the CdSe/ZnS 
quantum dots were obtained by using the equation[4]
 




	
where  and 0 are the average emission lifetimes in the presence and in the absence of quencher, 
respectively and n is the number of Mn complexes. 
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S5. Evidence of CO evolution upon irradiation.
Qualitative evidence of CO evolution was obtained via myoglobin (Mb) assay.[5] Complexes 1-4 were 
dissolved in DMSO and added as a 10-fold molar excess to an aqueous solution of reduced horse heart Mb 
having a 26 M concentration in the case of complexes 1 and 4 and a 31 M concentration in the case of 
complexes 2 and 3. In all cases denaturation of the protein (and subsequent scattering) occurs within the first 
15 minutes of irradiation. Prolonged irradiation leads to a complete denaturation and precipitation of the 
protein with consequent loss of signal. The lower Mb concentration in the case of complexes 1 and 4 is due 
to our efforts to minimize the effect outlined above.   
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Figure S10. Changes occurring in the UV-Vis spectra of a reduced myoglobin solution (black) upon addition 
of Mn(I) complexes 1-4 and subsequent irradiation at 510 nm (red). 
In the case of QD-Mn systems a THF solution was used due to the insolubility of such systems in DMSO. A 
pronounced scattering was observed upon addition the QD-Mn system to the 26 M aqueous Mb solution (as 
evidenced in Figure S11, see black and blue lines) as a consequence of QD-Mn precipitation in water. 
However, qualitative evidence of CO release upon irradiation (red line) could still be obtained within the 
timeframe of the experiment (15 min.). Analogously to what observed for complexes 1-4, prolonged 
irradiation leads to a complete denaturation and precipitation of the protein with consequent loss of signal. 
The typical spectral changes are shown in Figure S11 for QD-3. All other species show similar behaviours. 
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Figure S11. Changes occurring in the UV-Vis spectra of a reduced myoglobin solution (black) upon addition 
of QD-3 system (blue) and subsequent irradiation at 510 nm (red). 
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